399 related articles for article (PubMed ID: 28739923)
1. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
Li N; Fu H; Hewitt SM; Dimitrov DS; Ho M
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6623-E6631. PubMed ID: 28739923
[TBL] [Abstract][Full Text] [Related]
2. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
[TBL] [Abstract][Full Text] [Related]
3. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
[TBL] [Abstract][Full Text] [Related]
4. Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma.
Li N; Ho M
Methods Mol Biol; 2022; 2446():451-468. PubMed ID: 35157288
[TBL] [Abstract][Full Text] [Related]
5. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S; Bosse KR; Zhu Z; Zhelev D; Majzner RG; Radosevich MT; Dhingra S; Sotillo E; Buongervino S; Pascual-Pasto G; Garrigan E; Xu P; Huang J; Salzer B; Delaidelli A; Raman S; Cui H; Martinez B; Bornheimer SJ; Sahaf B; Alag A; Fetahu IS; Hasselblatt M; Parker KR; Anbunathan H; Hwang J; Huang M; Sakamoto K; Lacayo NJ; Klysz DD; Theruvath J; Vilches-Moure JG; Satpathy AT; Chang HY; Lehner M; Taschner-Mandl S; Julien JP; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL
Cancer Cell; 2022 Jan; 40(1):53-69.e9. PubMed ID: 34971569
[TBL] [Abstract][Full Text] [Related]
6. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.
Bosse KR; Raman P; Zhu Z; Lane M; Martinez D; Heitzeneder S; Rathi KS; Kendsersky NM; Randall M; Donovan L; Morrissy S; Sussman RT; Zhelev DV; Feng Y; Wang Y; Hwang J; Lopez G; Harenza JL; Wei JS; Pawel B; Bhatti T; Santi M; Ganguly A; Khan J; Marra MA; Taylor MD; Dimitrov DS; Mackall CL; Maris JM
Cancer Cell; 2017 Sep; 32(3):295-309.e12. PubMed ID: 28898695
[TBL] [Abstract][Full Text] [Related]
7. A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
Raman S; Buongervino SN; Lane MV; Zhelev DV; Zhu Z; Cui H; Martinez B; Martinez D; Wang Y; Upton K; Patel K; Rathi KS; Navia CT; Harmon DB; Li Y; Pawel B; Dimitrov DS; Maris JM; Julien JP; Bosse KR
Cell Rep Med; 2021 Jul; 2(7):100344. PubMed ID: 34337560
[TBL] [Abstract][Full Text] [Related]
8. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.
Tian M; Cheuk AT; Wei JS; Abdelmaksoud A; Chou HC; Milewski D; Kelly MC; Song YK; Dower CM; Li N; Qin H; Kim YY; Wu JT; Wen X; Benzaoui M; Masih KE; Wu X; Zhang Z; Badr S; Taylor N; Croix BS; Ho M; Khan J
J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35852863
[TBL] [Abstract][Full Text] [Related]
9. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
11. Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma.
Sun M; Cao Y; Okada R; Reyes-González JM; Stack HG; Qin H; Li N; Seibert C; Kelly MC; Ruppin E; Ho M; Thiele CJ; Nguyen R
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36631162
[TBL] [Abstract][Full Text] [Related]
12. GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.
Pascual-Pasto G; McIntyre B; Shraim R; Buongervino SN; Erbe AK; Zhelev DV; Sadirova S; Giudice AM; Martinez D; Garcia-Gerique L; Dimitrov DS; Sondel PM; Bosse KR
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460335
[TBL] [Abstract][Full Text] [Related]
13. Association between GPC2 polymorphisms and neuroblastoma risk in Chinese children.
Li M; Zhang X; Liu J; Zhou C; Miao L; He J; Wu H; Zhang R
J Clin Lab Anal; 2023 Mar; 37(5):e24866. PubMed ID: 36920409
[TBL] [Abstract][Full Text] [Related]
14. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of N‑Myc inhibits neuroblastoma cell growth via the Wnt/β‑catenin signaling pathway.
Wang Y; Gao S; Wang W; Xia Y; Liang J
Mol Med Rep; 2018 Jul; 18(1):377-384. PubMed ID: 29749516
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization.
Buongervino S; Lane MV; Garrigan E; Zhelev DV; Dimitrov DS; Bosse KR
Mol Cancer Ther; 2021 Nov; 20(11):2228-2239. PubMed ID: 34465595
[TBL] [Abstract][Full Text] [Related]
17. Glypican-5 suppresses Epithelial-Mesenchymal Transition of the lung adenocarcinoma by competitively binding to Wnt3a.
Wang S; Qiu M; Xia W; Xu Y; Mao Q; Wang J; Dong G; Xu L; Yang X; Yin R
Oncotarget; 2016 Nov; 7(48):79736-79746. PubMed ID: 27806326
[TBL] [Abstract][Full Text] [Related]
18. Wnt signalling is a bi-directional vulnerability of cancer cells.
Duffy DJ; Krstic A; Schwarzl T; Halasz M; Iljin K; Fey D; Haley B; Whilde J; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
Oncotarget; 2016 Sep; 7(37):60310-60331. PubMed ID: 27531891
[TBL] [Abstract][Full Text] [Related]
19. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
[TBL] [Abstract][Full Text] [Related]
20. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.
Feng M; Gao W; Wang R; Chen W; Man YG; Figg WD; Wang XW; Dimitrov DS; Ho M
Proc Natl Acad Sci U S A; 2013 Mar; 110(12):E1083-91. PubMed ID: 23471984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
